New Research Offers Hope for Better Malaria Treatment: EMBL Australia Burnet Institute Study

The Persistent Global Challenge of Malaria

Malaria, caused primarily by the Plasmodium falciparum parasite and transmitted through Anopheles mosquito bites, remains a formidable public health threat. According to the World Health Organization's World Malaria Report 2025, there were 282 million cases and 610,000 deaths in 2024 alone, with the majority affecting children under five in sub-Saharan Africa. 84 85 Despite progress since 2000, where interventions averted 2.3 billion cases and 14 million deaths, recent stagnation highlights emerging threats like drug resistance and funding gaps. 84 Current treatments, such as artemisinin-based combination therapies (ACTs), effectively clear parasites but fail to mitigate excessive inflammation, which exacerbates symptoms like fever, anemia, and cerebral malaria while impairing long-term immunity. This leaves survivors vulnerable to reinfections, perpetuating cycles in endemic areas.

In Australia, where malaria is not endemic, imported cases underscore the need for global solutions. Around 300-400 cases are reported annually, often among travelers, emphasizing the role of Australian research institutions in advancing treatments. 36

Australian Higher Education's Role in Combating Malaria

Australia's higher education sector punches above its weight in infectious disease research, with institutes like the Burnet Institute and EMBL Australia nodes embedded within university ecosystems. The Burnet Institute, closely affiliated with the University of Melbourne and Monash University, hosts world-class labs focused on malaria elimination. EMBL Australia, part of the European Molecular Biology Laboratory network, operates group leader positions at partner labs including Burnet, fostering cutting-edge biomedical research. 73

Funding from the National Health and Medical Research Council (NHMRC), Bill & Melinda Gates Foundation, and philanthropic sources like the Snow Medical Fellowship ($8 million to Dr. Michelle Boyle) sustains this work. 105 These efforts not only drive scientific breakthroughs but also create opportunities for PhD students, postdocs, and faculty. For those interested in research jobs in infectious diseases, Australia's collaborative environment offers pathways to impactful careers.

Introducing the Groundbreaking EMBL Australia and Burnet Study

The latest malaria treatment research from EMBL Australia and the Burnet Institute centers on host-directed therapy (HDT), a novel strategy targeting the human immune response rather than just the parasite. Published in Science Translational Medicine in 2025, the study titled "Adjunctive ruxolitinib attenuates inflammation and enhances immunity in volunteers experimentally infected with Plasmodium falciparum" demonstrates how adding ruxolitinib—a Janus kinase (JAK) 1/2 inhibitor approved for conditions like myelofibrosis—to standard ACTs can transform outcomes. 73 115

Led by Dr. Michelle Boyle, Associate Professor and EMBL Australia Group Leader at Burnet, the research addresses a critical gap: while ACTs kill parasites, inflammation hinders immunity development. Ruxolitinib blocks type I interferon signaling, reducing regulatory responses that suppress adaptive immunity. 62

Dr. Michelle Boyle: A Leader in Malaria Immunity Research

Dr. Michelle Boyle exemplifies excellence in Australian higher education research. As Deputy Program Director for Disease Elimination at Burnet Institute and Snow Medical Fellow, her work spans cellular immunity, vaccines, and therapeutics. Recruited as an EMBL Australia Group Leader in 2018, she has pioneered insights into CD4 T cells and antibodies protective against malaria. 62 Her team's Phase 1b trial marks a world's first in testing JAK inhibitors for malaria.

"We are excited about the potential of this approach, and are now working towards testing in patients with malaria in endemic countries," Dr. Boyle stated. 73 Collaborations with Monash University and international partners amplify her impact, inspiring the next generation of researchers via higher ed career advice.

Detailed Methodology: Controlled Human Infection Model

The study employed a rigorous double-blind, randomized, placebo-controlled design with 20 malaria-naïve healthy adults. Here's the step-by-step process:

• Day 0: Volunteers inoculated intravenously with blood-stage Plasmodium falciparum parasites.
• Days 1-7: Monitored for parasitemia via thick blood smears and PCR.
• Day 8: Upon reaching ~5000 parasites/µL, randomized 1:1 to receive artemether-lumefantrine (standard ACT) plus oral ruxolitinib (40mg twice daily for 3 days) or placebo.
• Post-treatment monitoring: Assessed inflammatory markers (e.g., C-reactive protein, angiopoietin-2, ICAM-1) and immune parameters.
• Day 90: Re-inoculation and repeat treatment (open-label ACT only) to evaluate immune memory.

This controlled human malaria infection (CHMI) model, ethically conducted in Australia, provides precise data unattainable in endemic settings. 115

Photo by Hanna Morris on Unsplash

Key Findings: Taming Inflammation and Boosting Immunity

Ruxolitinib significantly attenuated post-treatment inflammation. Participants showed reduced elevations in C-reactive protein (CRP)—a key inflammation marker—and disease severity indicators like angiopoietin-2 (Ang-2) and intercellular adhesion molecule-1 (ICAM-1), linked to vascular damage in severe malaria. 115

Upon rechallenge at 90 days, the ruxolitinib group exhibited enhanced immune memory, with upregulated HLA-DRA and 4-1BB expression on T cells, signaling stronger activation and antiparasitic responses. These changes suggest faster parasite clearance and durable protection.

• Lower inflammatory burden post-first infection.
• Improved T cell responses on rechallenge.
• Potential for fewer reinfections in children.

Safety Profile and Clinical Tolerability

Safety was paramount; ruxolitinib proved well-tolerated alongside ACTs, with no serious adverse events. Mild side effects, consistent with its approved uses, resolved quickly. This repurposing leverages existing pharmacokinetics data, accelerating translation.Read the full study here. 115

In context of rising artemisinin resistance—now in East Africa threatening ACT efficacy—this adjunct offers a complementary tool. 94

Implications for Endemic Regions and Drug Resistance

For children in high-burden areas, where repeated infections stunt immunity, HDT could reduce severe disease risk. Amid partial artemisinin resistance and stalled progress (only 47% mortality reduction since 2000 vs. 90% goal), adjuncts like ruxolitinib preserve ACT utility. 99 Australian research positions the country as a hub for such innovations, benefiting global health.

Stakeholder views: WHO urges new tools; experts hail HDT as vital.WHO Malaria Report

Future Outlook: From Bench to Bedside

Boyle's team plans pediatric trials in endemic sites like Papua New Guinea, leveraging Burnet's Malaria Synergy Program. Broader applications to other infections (e.g., Group A Strep) are explored. 104 NHMRC and Gates funding ($5M+ recently) fuels expansion. 108

In higher ed, this underscores demand for postdoc positions in immunology. Explore research assistant jobs to contribute.

Careers in Malaria Research: Opportunities in Australia

Australia's ecosystem offers roles from lab techs to professors. Burnet and EMBL seek talent for vaccine trials and epidemiology. With global needs rising, university jobs in higher ed provide stability and impact. Career advice for postdocs can guide your path.

Photo by Dayne Topkin on Unsplash

Conclusion: Hope on the Horizon

This EMBL Australia-Burnet study heralds a new era in malaria treatment research, blending parasite clearance with immune enhancement. As challenges persist, Australian higher ed leads solutions. Stay informed and engage via Rate My Professor, search higher ed jobs, or access higher ed career advice. Together, we advance toward elimination.